Phosphorylation Site Specific Aptamers for Cancer Biomarker Peptide Enrichment and Detection in Mass Spectrometry Based Proteomics

The development of renewable capture reagents that could be produced more efficiently and cost-effectively than monoclonal antibodies is a key topic in diagnostics and therapeutics. The cancer research community has demonstrated a critical need for these reagents for biomarker detection. Base Pair Biotechnologies has developed high-affinity aptamers against specific phosphorylated and unmodified peptide target sequences of certain cancer biomarkers of interest.